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The mammalian nuclear matrix is now recognized as a 
site of lipid biosynthesis and signaling in both normal and 
pathological states (reviewed in 1–8). Radioisotope and 
stable isotope tracer studies consistently identify glycero-
phospholipids (GPLs), and the enzymatic activities that 
metabolize them, within purified nuclear fractions pur-
portedly devoid of nuclear envelope and other cellular 
membrane contaminants (9–15). These findings suggest 
the existence of an independently-regulated GPL pool 
within the nuclear matrix, one distinct from the nuclear 
envelope and from bulk cellular membranes. In support 
of this interpretation, nuclear isoforms of a number of 
GPL metabolic enzymes have been described (10, 11, 16–
22). The STAR-PAP RNA poly-A polymerase, the direct 
modification of a phosphoinositide headgroup presented 
to an inositide kinase by a nuclear receptor, and nuclear 
phosphoinositide control of the basal transcription ma-
chinery all provide compelling examples of GPL-regulated 
activities that discharge their functions within the nuclear 
matrix (23–27). At issue, however, is the scale of nuclear 
GPL metabolism and nuclear GPL load.
This difficult question can now be addressed using 
quantitative mass spectrometric methods. The single ma-
jor study on this topic estimates that phosphatidylcholine 
(PtdCho) alone occupies 10–16% of the nuclear matrix of 
IRB-32 cells by volume (14). This is a startling conclusion 
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Assay Designs, Ann Arbor, MI; product number SPA-860), an 
anti-histone H3 antibody (generous gift of Brian Strahl, Univer-
sity of North Carolina-Chapel Hill), an anti-NURIM antibody 
(Santa Cruz Biotechnology, Santa Cruz, CA; product number 
sc-133260), and an anti-fibrillarin antibody (Abcam Inc., Cam-
bridge, MA; product number ab5821). Goat-anti-mouse or 
goat-anti-rabbit HRP-conjugated secondary antibodies (Bio-Rad, 
Hercules, CA) were used for development in ECL assays. Donkey-
anti-rabbit secondary antibody conjugated to IR Dye 800 was 
purchased from Rockland Immunochemicals Inc. (Gilbertsville, 
PA; product number 611-731-127) for use in Odyssey immunob-
lotting experiments.
Cell culture and transfection
iMEFs were derived from E14-E16 embryos, and immortalized 
iMEF lines were generated using the SV40 large T-antigen 
method (28). Unless otherwise specified, all primary and immor-
talized cell lines were cultured in complete DMEM containing 
4.5 g/l glucose and supplemented with 10% FBS, 1 U/ml penicil-
lin G, and 100 g/ml streptomycin (complete DMEM). All cell 
culture was performed at 37°C in a 10% CO2 incubator.
Initial steps in purifying envelope-stripped iMEF nuclei
Envelope-stripped nuclei were prepared using the method of 
Martelli et al. (11) with essential modifications: iMEF cells were 
seeded to 150 mm tissue culture dishes and grown for 24–48 h. 
Approximately 107 iMEFs were pelleted (for a 1× preparation) 
and washed three times in Dulbecco’s PBS solution. After com-
plete removal of PBS, the cell pellet was resuspended thoroughly 
in 500 l of chilled buffer A [10 mM Tris-HCl (pH 7.4), 1% NP-
40, 10 mM -mercaptoethanol, 0.5 mM PMSF] supplemented 
with Complete Protease Inhibitor cocktail (Roche Biopharma-
ceuticals). Cells were incubated on ice for 8 min with occasional 
agitation. An equal volume of ice-cold ddH2O was added to swell 
the cells. Following a 3 min incubation, swollen cells were subse-
quently subjected to three passages through a 22 gauge needle. 
Removal of cellular debris was monitored by examination of sev-
eral microliters of triturate by phase contrast microscopy. In suf-
ficiently sheared samples, minimally 40 of 50 nuclei examined 
lacked significant cytosolic or membranous debris. After addi-
tion of 0.5 ml of chilled buffer B [10 mM Tris-HCl (pH 7.4), 2 
mM MgCl2] supplemented with protease inhibitors, the nuclei 
were gently triturated and again examined by microscopy. Nuclei 
were returned to ice for 1 min in preparation for centrifugation, 
during which a portion of lysate (representing the whole cell 
fraction) was saved for immunoblot analysis of cellular markers 
and total protein quantification.
Ultimate steps in purifying envelope-stripped iMEF 
nuclei
Nuclei were sedimented at 86 g for 10 min at 4°C. The superna-
tant (cytosolic fraction) was either discarded or saved for quality 
control analysis as needed. The crude pellets were washed once 
with an excess of buffer B and sedimented again at 86 g for 10 min 
at 4°C. During an unscaled preparation, the purified nuclei were 
resuspended in buffer B and distributed as necessary for quality 
control protein analyses. When generating three times purified 
nuclear pellets for analysis of PLs by ESI LC-MS, the purified pellet 
was instead resuspended in 1 ml total of buffer B. Of this suspen-
sion, 85% of the final material was pelleted at 500 g for 2 min at 4°C. 
Following complete removal of the supernatant, the pellet was 
snap-frozen in liquid nitrogen and stored at 80°C in preparation 
for PL analysis by MS. Aliquots (150 l) were collected for protein 
measurements and quality controls before the final pelleting step.
considering that the genome itself is estimated to occupy 
some 39% of the nuclear volume in the IMF-32 cell line. 
Furthermore, the endonuclear GPL pool is reported to be 
unusual in that it is dominated by saturated PtdCho mo-
lecular species (14). The abundance of endonuclear 
GPLs, when coupled with their predominantly saturated 
nature, motivates speculation that phospholipids (PLs) 
profoundly influence the chemical properties of the nu-
clear matrix, i.e., by contributing to the formation of gel-
like regions within the nuclear matrix (1, 14). This concept 
raises a fundamental question of how does the nuclear 
matrix accommodate such a large PL load? That is, how 
are lipids organized within the nuclear matrix?
Given the mounting evidence for endonuclear lipid sig-
naling and the lingering questions regarding how lipids 
are organized in nuclear matrix, we reinvestigated the 
problem of endonuclear lipidomics. To this end, we devel-
oped a reliable and reproducible method for purification 
of envelope-free nuclei from immortalized murine embry-
onic fibroblasts (iMEFs). This method adheres to a strin-
gent quality-control regime for assessing purity of isolated 
endonuclear compartments. Quantitative GPL profiling 
of these highly purified fractions describes an endonu-
clear GPL composition that is indeed distinct from that of 
bulk cellular membrane. Contrary to previous reports, 
however, the profile shows no particular enrichment of 
saturated GPL molecular species. Moreover, the mass 
measurements record drastically lower GPL contents in 
endonuclear compartments than those previously reported, 
at least for a neuroblastoma cell line. While the collective 
data confirm the nuclear matrix harbors a GPL pool of 
distinct composition from that of bulk membrane, the 
data also identify the iMEF nuclear matrix as a PL-poor 
environment that requires no unusual provisions for PL 
accommodation other than binding to resident proteins.
MATERIALS AND METHODS
Reagents and general notes
Chemicals and reagents were purchased from Fisher Scientific 
(Pittsburg, PA) or from Sigma-Aldrich (St. Louis, MO), unless 
otherwise stated. All lipid standards were purchased from Avanti 
Polar Lipids (Alabaster, AL). Organic solvents and supplies used 
to prepare samples for electron microscopy (EM) were obtained 
from Electron Microscopy Sciences (Hatfield, PA). The mass la-
bels, myo-inositol-d6 and choline-d9, were obtained from C/D/N 
Isotopes (Pont-Claire, Quebec, Canada) and Sigma-Aldrich, 
respectively.
Media and antibodies
DMEM and antibiotics were obtained from Gibco/Invitrogen 
(Carlsbad, CA). FBS was obtained from Gemini Bio-products 
(Sacramento, CA). A mouse monoclonal antibody directed to-
ward -tubulin (product number T5293) and rabbit polyclonal 
antibody directed toward lamin A (product number L1293) were 
obtained from Sigma-Aldrich. A mouse monoclonal antibody toward 
-tubulin was obtained from Neomarkers Inc. (Fremont, CA; 
product number MS-581-P). Other rabbit polyclonal antibodies 
utilized in this study include: an anti-calnexin antibody (Stressgen 
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OR), equipped with a Gatan model 794 multiscan digital 
camera.
To examine nuclei at different stages of purification, samples 
were fixed during extraction, shearing, and “unveiling” stages 
(see Results) of separate 1× preparations. Nuclei undergoing the 
initial extraction in buffer A (500 l total volume) were diluted 
to 10 ml with an excess of fixative [2% glutaraldehyde, 1% tannic 
acid, 2 mM CaCl2 in 0.1 M sodium cacodylate (pH 7.4)]. Nuclei 
were fixed at the 6 min time point. Sheared nuclei (1 ml) and 
“unveiled” nuclei (1.5 ml) were also diluted to the same final 
volume in fixative. One milliliter of each dilution was pelleted at 
100 g for 10 min at 4°C. Fixed samples were washed two times for 
10 min in 1 ml fixative. After washing thoroughly in buffer [2 mM 
CaCl2, 0.1 M sodium cacodylate( pH 7.4)], samples were pro-
cessed for EM as described above.
Profiling of bulk iMEF PL
To generate iMEF pellets for bulk cellular GPL analysis, 1.2 × 
106 cells were seeded onto 150 mm tissue culture dishes and 
grown for 24 h to 60–70% confluence. Some 107 cells were har-
vested by trypsinization, pelleted, and washed two times in HBSS 
without Ca2+ or Mg2+. Cells were then transferred to microfuge 
tubes in 1 ml of the same buffer and pelleted at 1,000 g for 5 min. 
Following complete removal of the supernatant, pellets were fro-
zen in liquid nitrogen and stored at 80°C prior to lipid extrac-
tion and global PL quantification by MS.
GPL extraction and analyses
GPLs from whole cells or nuclear pellets were extracted using 
a modified Bligh and Dyer procedure (29). Approximately 1 × 
107 iMEF cells or 3 × 107 nuclei per pellet in cold 1.5 ml mi-
crofuge tubes (Laboratory Product Sales, Rochester, NY) were 
vortexed with 800 l of cold 0.1 N HCl:CH3OH (1:1) and 400 l 
of cold CHCl3 was added. The extraction proceeded with vortex-
ing (1 min) and centrifugation (5 min, 4°C, 18,000 g). Quantifi-
cation of GPLs was achieved by the use of ESI LC-MS employing 
synthetic (non-naturally occurring) diacyl and lysophospholipid 
standards as communicated elsewhere (30). Typically, 200 ng of 
each odd-carbon standard was added to each sample. Identifica-
tion of the individual PLs was accomplished by LC-MS/MS using 
an MDS  SCIEX  4000 QTRAP  hybrid  triple  quadrupole/linear 
ion trap mass spectrometer and a Shimadzu HPLC system with a 
normal phase Luna Silica column (2 × 250 mm, 5 m) using a 
gradient elution (30). Identification of the individual species was 
based on their chromatographic and mass spectral characteris-
tics and comparison to these of chemically defined standards 
(30, 31). This analysis allows identification of both fatty acid moi-
eties, but does not determine position on the glycerol backbone 
(sn-1 vs. sn-2).
Statistical analyses
Data are presented as means plus standard errors. Differences 
between percentages of the total GPL pool represented by differ-
ent classes for whole cells versus nuclei were determined by Stu-
dent’s t-test.
Molecular biology and site-directed mutagenesis
Rat PITP cDNA was amplified by PCR and subcloned as a 
0.85 kb HindIII-BamHI fragment into pEGFP-N1 (Clontech, Palo 
Alto, CA). A HA-tagged rat PITP cDNA (C-terminal tag) was 
generated by amplification of the rat PITP cDNA and insertion 
of the 0.85 kb product into the unique BamHI-NotI sites of 
pEF3HA, a derivative of pEF4 (Invitrogen, Carlsbad, CA). This 
construct contains a HA epitope that was incorporated into that 
Immunoblot analyses of envelope-free nuclei
In preparation for immunoblot analysis, whole cell lysates, 
wash fractions, and nuclear pellets were homogenized in M-Per 
lysis buffer (Thermo Scientific) supplemented with Complete 
Protease Inhibitor Cocktail (Roche Biopharmaceuticals). Sam-
ples were triturated vigorously through a 25 gauge needle until 
complete sample disruption was achieved (as confirmed by phase 
contrast microscopy). Samples were clarified by centrifugation, 
and the supernatant was separated to a fresh tube for protein 
precipitation using the SDS-PAGE Clean-up kit (GE Life Sci-
ences, Piscataway, NJ) according to the manufacturer’s direc-
tions. Precipitates were resuspended in CHAPS buffer (8 M urea, 
2% CHAPS, and 50 mM DTT). These samples were solubilized in 
Laemmli sample buffer resolved by SDS-PAGE (10% gels), and 
nuclear and membrane markers were visualized by immunoblot-
ting. Sample loading was normalized by “cell equivalents.” For 
Odyssey Westerns, the range of signal linearity was determined 
for each fraction with each antibody.
Resolved proteins were transferred to nitrocellulose mem-
branes by standard methods. Membranes were blocked in the 
appropriate blocking reagent (as recommended by the manufac-
turer) for 1 h at room temperature and probed with primary an-
tibody overnight at 4°C. Decorated membranes were washed 
three times for 10 min in TTBS and incubated for an additional 
1–2 h with the corresponding HRP-conjugated secondary anti-
body diluted in 2% BSA in TTBS. Blots were again washed three 
times in TTBS and once in PBS before development using the 
ECL method (Amersham Biosciences). We define the threshold 
for acceptable purity as lack of detectable calnexin immunoreac-
tivity in a nuclear preparation of 2.4 × 105 cell equivalents.
For detection of blotted proteins using the Odyssey platform, 
transferred membranes were blocked for 1 h at room tempera-
ture in Odyssey blocking buffer (LI-COR Biotechnology, Lin-
coln, NE). The appropriate primary and secondary antibodies 
were diluted in a 1:1 solution of Odyssey blocking buffer and 
PBS. Secondary incubations and terminal wash steps were per-
formed in the dark. Decorated membranes were analyzed on the 
Odyssey® infrared imaging system using Odyssey® 2.0 software 
(LI-COR Biotechnology). Scan settings were high image quality, 
resolution was set to 169 m, and the intensity of the scan was 
5.0. Antibody signals were quantified as integrated intensities of 
the areas above and below the bands of interest.
Quantification of cellular protein
Prior to protein quantification, cellular fractions were recon-
stituted in 1% SDS and incubated at 95°C for 10 min. Cooled 
samples were homogenized by at least 30 passages through a 25 
gauge needle. Satisfactory sample disruption was confirmed by 
phase microscopy and samples were subsequently clarified by 
centrifugation. In preparation for BCA analysis (Thermo Scien-
tific, Rockland, IL), samples were diluted 1:10 or 1:20. Diluted 
fractions were analyzed in triplicate according to the protocol for 
BCA assay for microplate reader.
EM of envelope-free nuclei
Purified nuclei were pelleted and fixed in 2% glutaraldehyde, 
1% tannic acid in 0.1 M sodium cacodylate, 2 mM CaCl2, and 
postfixed in 2% OsO4 in 0.1 M sodium cacodylate, 2 mM CaCl2. 
Samples were stained in 4% uranyl acetate in 50% ethanol, dehy-
drated  in a 50–100% ethanol/water  series,  cleared with pro-
pylene oxide, and embedded in Embed-812 resin (Electron 
Microscopy Sciences). Ultrathin sections (50 m) were prepared 
using a Leica UCT ultramicrotome, and images were acquired 
with a Tecnai 12 transmission electron microscope (FEI, Hillsboro, 
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fibroblast (MEF) system for addressing questions related 
to nuclear signaling, we developed a method for prepar-
ing highly purified envelope-free nuclei from these cells. 
The method generated purified endonuclear compart-
ments suitable for quantitative lipidomic analyses and 
yielded reproducible data. The procedure employed serial 
stripping manipulations in the presence of detergent (1% 
NP-40), and hypotonic swelling and mechanical shearing 
in progressively more dilute detergent environments (1% 
→ 0.5% → 0.33% → 0% NP-40) to arrive at envelope-free 
nuclear preparations.
As a general comment, our protocol for purification of 
envelope-free nuclei worked optimally when 1 × 107 pri-
mary or iMEF cells were used as starting material (termed 
a 1× scale). The efficacy of the method is sensitive to scale 
and applications that require larger mass quantities of nu-
clei are best served by generating several smaller nuclear 
preparations in parallel and pooling the corresponding 
PL extracts. We recommend processing no more than 
3 × 107 cells during a single purification. Buffer volumes 
used in preparing larger samples should be scaled accord-
ingly. A methodological flowchart is depicted in Fig. 1. 
From nine independent 1× preparations of envelope-free 
nuclei, an average of 0.34 ± 0.10 mg of endonuclear pro-
tein was recovered. As the averaged 1× quantity of total 
cellular starting material was 3.11 ± 0.45 mg of total cellu-
lar protein, the final protein yield in the purified endo-
nuclear fractions was approximately 10% of total starting 
material.
Visual landmarks for monitoring purification quality
Several morphological transformations accompanied 
separation of the nuclear particle from contaminating cel-
lular membranes and nuclear envelope. These transfor-
mations were readily observed during the purification and 
reliably diagnosed quality of the final preparation. As 
such, these morphological landmarks served as valuable 
real-time reporters of processing efficacy. The stages of 
processing at which these transformations were monitored 
are highlighted in Figs. 2, 3. Typical nuclear morphologies 
observed during the initial detergent extraction step (1% 
NP-40) are shown in Fig. 2B. The nuclear particles were 
readily distinguished from assorted cytosolic and organ-
elle debris by light microscopic examination at 40× magni-
fication. The efficacy of the hypotonic swelling step (NP-40 
diluted to 0.5% at this step) was similarly interpretable as 
nuclei increased slightly in diameter (Fig. 2C).
A subsequent and effective shearing step was an essen-
tial component of the purification. Rapid and vigorous 
trituration of crude nuclear fractions through a 22 gauge 
needle liberated nuclei of associated debris and left the 
sheared nuclei as oblate particles. Satisfactory outcomes at 
this stage were defined by lack of associated large debris in 
at least 40 of 50 nuclear particles examined. Examples of 
typical nuclear morphologies at this stage are shown in 
Fig. 2D, E. EM analyses demonstrated that cellular debris 
attached to the detergent-extracted nuclear particle (Fig. 
2F) was mostly removed by the shearing step (Fig. 2G). 
Although a small amount of debris remained attached to 
construct as an XbaI-PmeI cassette (DNA sequence 5′-TATCCT-
TACGAC GTTCCAGACTATGCA-3′). Site-directed mutagenesis 
primers used in this study were from Fisher Scientific, and rat 
PITP cDNAs were mutagenized according to QuickChange mu-
tagenesis kit specifications (Stratagene, La Jolla, CA). All mutant 
constructs were confirmed by nucleotide sequence analysis.
Transient transfection of mammalian cell lines
Immortalized cell lines were transfected using the FuGene 
transfection reagent (Roche, Indianapolis, IN). Briefly, Cos7 
cells or HeLa lines were seeded onto plastic dishes in complete 
DMEM 24 h prior to transfection. Once cells settled on the plas-
tic surface, the medium was exchanged for antibiotic-free DMEM. 
One microgram aliquots of PITP-EGFP constructs were incubated 
in 100 l Opti-MEM (Invitrogen) premixed with 3 l transfection 
reagent according to the manufacturer’s instructions. The com-
plete transfection cocktail was incubated at room temperature 
for 1 h before distribution to the medium. At 12 h posttransfection, 
cells were split onto coverslips and cultured in complete DMEM.
Immunocytochemistry
HeLa or Cos7 cells, transiently transfected with appropriate 
PITP-EGFP or PITP-HA expression plasmids, were fixed 16–20 
h posttransfection in 4% PFA in PBS. After permeabilization in 
0.2% Triton X-100, cells expressing PITP-EGFP constructs were 
counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (Mo-
lecular Probes) for 1 min. Cells transfected with PITP-HA con-
structs were permeabilized similarly, then incubated for 1 h at 
room temperature in blocking buffer (2% BSA in PBS). Primary 
anti-HA antibodies (1:2,000 dilution in blocking buffer) were ap-
plied to blocked coverslips. After a 12–15 h incubation of cover-
slips with primary antibody at 4°C, cells were serially washed 
three times for 10 min in 1% BSA in PBS. Secondary antibodies 
(1:8,000 in blocking buffer) were then applied onto coverslips 
and fixed cells were incubated at 4°C for 5–8 h. After several 
washes (1% BSA in PBS), cells were counterstained with DAPI. 
Coverslips were mounted on glass slides, imaged on a Zeiss 510 
META scanning laser confocal microscope, and images were pro-
cessed using Adobe Photoshop 6.0.
Labeling iMEF cells in culture with deuterated GPL 
precursors
PITP+/+ or pitp0/0 iMEFs were seeded in complete DMEM 
and grown to a subconfluent (60%) density. Cells were washed 
in PBS and labeled for the desired time period in antibiotic-free 
DMEM containing 10% FBS, 80 g/ml choline-d9, and 50 g/ml 
myo-inositol-d6. For whole cell measurements, PITP
+/+ or pitp0/0 
iMEFs were collected in 800 l HBSS for GPL extraction and 
analysis by LC-MS/MS. In experiments involving purified nuclei 
stripped of membranes, 3 × 107 cells were pelleted and washed in 
PBS prior to detergent-mediated removal of the nuclear enve-
lope. Extracts pooled from three samples (9 × 107 nuclei) were 
isolated and analyzed by LC-MS.
RESULTS
Purification of envelope-free iMEF nuclei
Purification of quality envelope-free nuclei requires 
comprehensive removal of contaminating cellular mem-
branes and nuclear envelope with minimal compromise of 
nuclear integrity or of the biochemical character of the 
nuclear matrix. Because of the experimental advantages 
offered by the genetically tractable murine embryonic 
1496 Journal of Lipid Research Volume 57, 2016
higher magnification (>10,000×) by EM, the peripheries 
of individual nuclear particles presented a fuzzy border 
and the obvious membrane bilayer structures that consti-
tute the nuclear envelope were no longer visible at these 
peripheries (compare Fig. 5C, E with Fig. 5D, F, respec-
tively). However, the high resolution EM analyses detected 
two classes of impurities that commonly evade detection 
by lower magnification EM, i.e., the types of analyses typi-
cally presented as evidence for the envelope-free status of 
purified nuclear particles (14). First, small copurifying 
membrane-like strands, attached to the isolated nuclear 
particles, were occasionally observed (Fig. 5H). Second, 
these structures were also occasionally observed in the ab-
sence of an attached nucleus, and those were counted as 
well (Fig. 5G). Typically, two strands were recorded per 
100 nuclei, and one small patch (average length 500 
nm) was identified per 34 nuclei (Fig. 5H). We found this 
low level of potential contamination to be unavoidable. 
For purposes of reference, supplementary Table 1 com-
piles the contamination data over a series of independent 
nuclear preparations.
Biochemical criteria for purified envelope-free nuclei
The accepted biochemical standard for envelope-free nu-
clei is the absence of the abundant cytosolic protein, -
tubulin, in the most purified fractions (14, 21, 32, 33). 
Unfortunately, this criterion does not adequately interro-
gate the preparation for contamination by the nuclear en-
velope, a membrane system physically contiguous with the 
highly abundant endoplasmic reticulum (ER). To control 
nuclei at this stage, closer examination of nuclear borders 
revealed that shearing removed the majority of the nu-
clear envelope (Fig. 2H).
Upon further dilution of suitably sheared nuclei into 
Mg2+-containing buffer B (final NP-40 concentration at 
this stage is 0.33%), the nuclear envelope was effectively 
removed. This stripping event was monitored via phase 
contrast microscopy by what we term an unveiling process. 
Unveiling was marked by the nuclei becoming less opaque 
and the nucleoli assuming much sharper contrast relative 
to nucleoplasm (Fig. 3B). The loss of nuclear envelope was 
visible in electron micrographs of nuclei fixed immedi-
ately after addition of buffer B (Fig. 3C, left two panels). 
Borders of stripped nuclei appear fuzzy and without dis-
cernable traces of nuclear envelope (Fig. 3C, right two 
panels). Subsequent pelleting and washing steps in buffer 
B (no detergent present) completed the envelope strip-
ping process (Fig. 4). Purified nuclei retained their mor-
phologies and appearance throughout the purification.
Imaging criteria for envelope-free nuclei
Visualization of envelope-stripped nuclei by EM directly 
interrogated the membrane content of nuclear prepara-
tions. When compared with in situ nuclear morphologies 
(Fig. 5A), low-magnification (<2,000×) electron micro-
graphs of purified envelope-free nuclei (Fig. 5B) demon-
strate efficient removal of extraneous material. Nuclear 
structure was nicely preserved, and contaminating organ-
elles or other heterogeneous membrane debris were not 
apparent at this level of resolution. When inspected at 
Fig. 1. Nuclear purification scheme. A schematic 
flow diagram for rapid purification of envelope-
stripped iMEF nuclei is illustrated. Total protein in 
individual fractions generated during the nuclear pu-
rification process is shown (milligrams).
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described herein exhibited undetectable levels of the abun-
dant integral ER membrane protein, calnexin, and the in-
ner nuclear envelope integral membrane protein, NURIM, 
in addition to undetectable levels of -tubulin (Fig. 6A). We 
for these primary sources of contaminating membranes, we 
monitored membrane-free nuclear preparations for abun-
dant integral membrane proteins of the ER and nuclear 
envelope. Endonuclear fractions purified by the protocol 
Fig. 2. Phase contrast monitoring of nuclear particles. A: Flow chart of the critical steps for removing ex-
tranuclear debris is indicated. All steps are executed on ice using chilled solutions and tubes. Eye symbols 
identify points where extraction efficacy is monitored by phase contrast microscopy. B–E: Phase contrast 
images of extracting nuclei at various steps during the purification. All images were taken using a 40× objec-
tive, and 3–5 l of sample was typically viewed under a coverslip. B: Cells are resuspended in buffer A to initi-
ate the extraction process. At this stage, nuclei are visible as the phase dense center of each cellular particle. 
Partially  solubilized cytoplasm/plasma membrane contaminants  are discerned as  the  less dense material 
surrounding the nuclear particle. C: Addition of an equal volume of chilled ddH2O swells the nuclei and 
further enhances contaminating material. D, E: Images of swollen nuclei sheared three times through a 22 
gauge needle. D: Successfully sheared nuclei exhibit little to no visible debris attached. E: Nuclei marked 
with an asterisk retain attached debris. Nuclei marked with arrowheads are scored as at a suitable stage of 
purification. F–H: Electron micrographs of nuclear preparation stages. F: Electron micrograph of nucleus 
(1,100×) fixed after 6 min of extraction in buffer A (scale bar = 2 m). G: Sheared nucleus (1,100×). Minor 
amounts of debris are still attached to the lamin boundary, which is clearly visible (scale bar = 2 m). H: 
Higher magnification (15,000×) image of a nuclear border that has been successfully stripped of envelope 
(scale bar = 0.2 m).
Fig. 3. Unveiling of sheared nuclei. A: Diagram of 
prepelleting purification steps. B: Phase contrast im-
ages of nuclei following addition of buffer B. Images 
were taken using a 40× objective. Portions of images at 
this magnification were digitally enlarged and are 
shown to the right. At this stage, nuclear particles 
show increased contrast and nucleoli become visible. 
C: Electron micrographs of nuclei, fixed immediately 
after addition of buffer B. In the two leftmost panels, 
intact nuclei are observed with no attached debris at 
low magnification. High magnification images of nu-
clear borders (two rightmost panels) demonstrate re-
moval of the nuclear envelope at this stage.
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defined the threshold for acceptable nuclear matrix purity 
as lack of detectable calnexin immunoreactivity in a sample 
of 2.4 × 105 nuclei in ECL immunoblotting experiments. 
Odyssey immunoblotting experiments indicated that less 
than 0.3% of cellular calnexin remained in nuclear prepa-
rations (Fig. 6B), reporting a <300-fold enrichment of nu-
clear particles from contaminating ER membranes.
The endonuclear fractions were highly enriched for the 
nuclear matrix constituent, lamin A, however (Fig. 6A). 
Enrichment of the nucleolar protein, fibrillarin, was also 
monitored. Fibrillarin localizes to the nucleoplasm as well 
as to nucleoli (34), and thus served as a marker for loss of 
both nucleoplasm and nucleoli. Based on quantitative im-
munoblotting data, we again estimated at least a 250-fold 
purification of nuclear matrix components (i.e., fibrilla-
rin) with respect to contaminating ER membrane protein 
(i.e., calnexin).
Total PL in cells and nuclei
The resident GPLs were quantified and their composi-
tions profiled in purified endonuclear compartments. 
Based on a signal-to-noise ratio of >3 as limit of detection 
threshold, we found the nuclear matrix to be a GPL-poor 
compartment. PtdCho, phosphatidylethanolamine (PtdEtn), 
phosphatidylserine (PtdSer), phosphatidylinositol (PtdIns), 
phosphatidic acid (PtdOH), and phosphatidylglycerol 
(PtdGro) were all detected in the endonuclear compart-
ment, in rank order of mass abundance. The total GPL mass 
measured per unit endonuclear compartment (0.077 ± 
0.0075 nmol/106 cells) projected an estimated load of ap-
proximately 5.9 × 107 GPL molecules per nuclear particle. 
Based on this value, and our estimate that the average iMEF 
nucleus occupies a volume of approximately 600 m3, we 
calculated that the GPL component occupies <0.1% of the 
iMEF nucleoplasm. As expected, endonuclear GPL load 
was small relative to whole cell amounts. The endonuclear 
GPL mass was almost two orders of magnitude less than 
that measured per unit iMEF cell (5.1 ± 0.43 nmol/106 cells). 
Fig. 4. Morphology of purified nuclei. Purified envelope-free 
nuclear fractions were imaged by phase contrast using a 40× objec-
tive. Left panel: Nuclear particles are prone to aggregation after 
envelope removal. Right panels: Inspection of smaller groups of 
purified nuclear particles confirms that individual particles do not 
change shape or appearance during the final centrifugation steps 
of the purification process.
Fig. 5. Electron microscopic analysis of envelope-free nuclear 
preparations. A: Whole iMEF cell. Nucleus is centered (1,100× 
magnification, scale bar = 2 m). B: Three purified nuclear parti-
cles at 1,100× magnification. Nuclei are free of membrane and cel-
lular debris, as evidenced by the clear background (scale bar = 
2 m). C: Nucleocytoplasmic boundary in whole iMEF cells. The 
nuclear envelope (NE) and its inner and outer leaflets are ob-
served at 11,000× magnification, separating the nuclear contents 
(N) from the cytosolic portion of the cell (C) (scale bar = 0.2 m). 
D: Nuclear boundary after envelope removal. At magnifications 
greater than 10,000×, envelope-stripped borders of nuclei appear 
dark and fuzzy (arrows). This is due to the osmophilic nature of the 
lamin boundary and condensed chromatin at the nuclear periph-
ery, which is no longer attached to the nuclear envelope. E: High 
magnification images of nuclear boundary in an intact iMEF cell. 
At 30,000× magnification, the outer nuclear envelope (ONM) sits 
above the inner nuclear envelope (INM), which is bound tightly to 
the underlying lamin border (scale bar = 0.1 m) F: High magnifi-
cation image (30,000×) of two juxtaposed nuclei. Bidirectional ar-
row directs attention to the borders of the two purified nuclei, 
which lack discernable traces of bilayer (scale bar = 0.1 m). G, H: 
Identifying membrane contaminants. Membrane strands are indi-
cated by arrows. G: Scanning nuclear peripheries for membrane 
contaminants at magnifications higher than 10,000× enables detec-
tion of free membrane strands (15,000× magnification, scale bar = 
0.2 m). H: High magnification (42,000×) micrograph of two jux-
taposed nuclei and a contaminating membrane patch (arrow) 
(scale bar = 50 nm). In quality preparations, no nuclei retain 
patches of membrane greater than 2 m in length and contaminat-
ing membrane is most commonly a very small patch, on average 
500 nm in length.
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the 32:0 and 30:0 PtdCho were the only saturated PtdCho 
molecular species of sufficient abundance to justify quan-
tification in the endonuclear fractions. Reciprocally, the 
polyunsaturated PtdCho species were only modestly re-
duced in abundance in the nuclear matrix relative to their 
representation in bulk GPL. The relative pool contribu-
tions of monounsaturated PtdCho species did not signifi-
cantly differ in endonuclear compartments versus bulk 
cell material (Fig. 7B, middle row).
These profiling data were inconsistent with strong 
enrichments of saturated PtdCho molecular species in 
envelope-free nuclear preparations. Indeed, unsaturated 
PtdCho molecular species compromised 79% of the total 
endonuclear PtdCho mass (Fig. 7). This pattern was ob-
served across the other GPL classes as well. Inspection of 
the rank order of the 42 most abundant endonuclear GPLs 
revealed a general paucity in both diversity and mass abun-
dance of saturated species (supplementary Table 2). For 
example, only 30% of the PtdSer mass was represented by 
saturated molecular species, and this fraction was much 
larger than for any other quantifiable endonuclear GPL 
class. PtdSer represented the third most abundant nuclear 
GPL class, comprising some 15% of the total endonuclear 
GPL mass. The preponderance of unsaturated GPLs was 
encouraging given the legitimate concern that detergent-
mediated stripping of the nuclear envelope might gener-
ate artifactual detergent-insoluble lipid domains expected 
to be enriched in saturated GPL molecular species and 
sphingolipids. In that regard, SM was at the limit of detec-
tion in endonuclear fractions, indicating this sphingolipid 
Thus, the iMEF endonuclear phospholipidome accounts 
for 1.4% of the total cellular GPL mass.
Lipidomic profiling of the major endonuclear PLs
With regard to composition, the bulk iMEF phospho-
lipidome presented a diverse signature, with the leading 
GPL classes (by mass) represented by PtdCho, PtdEtn, and 
PtdSer molecular species, respectively (supplementrary 
Table 2). We note that 38:4 PtdIns was also represented 
within the 10 most abundant bulk GPL species. By con-
trast, the iMEF endonuclear phospholipidome was domi-
nated (in mass terms) by PtdCho, PtdEtn, and PtdSer 
molecular species; whereas PtdIns, PtdOH, and PtdGro 
were poorly represented in endonuclear compartments. 
Interestingly, and as discussed in greater detail below, the 
differences in fractional representation of these minor 
PLs in bulk membranes versus the endonuclear compart-
ment were highly significant (P < 0.001). By contrast, the 
PtdCho/PtdEtn ratios  for  these  two systems were similar 
(approximately 1.85). We interpret the relative paucity of 
PtdIns, PtdOH, and PtdGro to argue against the measured 
endonuclear GPLs representing mere contamination 
from bulk ER (see Discussion).
PtdCho was the most abundant endonuclear PL class, 
represented by 9 of the top 10 most abundant molecular 
species (supplementary Table S2). Greater than half of 
the endonuclear GPL mass was accounted for by PtdCho 
species (53.1 ± 2.8%). The proportion of the PtdCho pool 
represented by saturated molecular species was only modestly 
increased in nuclei relative to whole cells. In that regard, 
Fig. 6. Immunoblot analyses of nuclear fractions. A: ECL immunoblot analysis of whole cell (WC) and purified nuclear fractions (NUC). 
Fractions collected from three separate nuclear preparations were prepared for gel electrophoresis as described in the Materials and Meth-
ods. Gels were loaded by cell equivalents based on the amount of whole cell lysate needed for blotting in the linear range. Comparison to 
a 4-fold excess of purified nuclei (4× PUR) highlights the absence/enrichment of cellular proteins in nuclear fractions. B: Odyssey immu-
noblot analysis of calnexin and fibrillarin content in whole cell, cytosolic, and 4× nuclear fractions from a single preparation. Each sample 
was loaded in triplicate. Gels were loaded with 15,000, 30,000, and 60,000 cell equivalents of both whole cell (WC) and cytosolic (CYT) 
protein fractions, whereas 60,000, 120,000, and 240,000 cell equivalents of purified nuclear protein were loaded for analysis. Relative inten-
sity of each individual band was quantified using the Odyssey 2.0 software. These values are listed below the image underneath the corre-
sponding bands. CNX, calnexin; FIBR, fibrillarin.
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whereas the most abundant endonuclear PtdIns was the 
38:4 molecular species, the only detectable PtdOH in this 
compartment was the 36:2 molecular species. In that re-
gard, none of the three acyl chain configurations identi-
fied for endonuclear PtdIns were of the 36:2 variety. Those 
data were inconsistent with a simple nucleoplasmic phos-
pholipase C-diacylglycerol kinase pathway. The action of 
such a metabolic sequence is expected to yield endonu-
clear 38:4 PtdOH (see Discussion).
Considerations for how PtdIns is imported into the 
nuclear matrix
The existence of endonuclear phosphoinositide biosyn-
thetic and signaling pathways begs the question of how 
PtdIns is incorporated into the nuclear matrix. The nu-
clear matrix has no capacity to produce PtdIns in situ 
given that PtdIns synthase is an integral membrane pro-
tein  of  the  ER.  The  PtdIns/PtdCho-transfer  protein, 
PITP, exhibits both cytoplasmic and endonuclear pools 
(33, 35, 36), raising the possibility that PITP shuttles 
PtdIns into the nuclear matrix. The low steady-state mass 
quantities of PtdIns we measured in the nuclear matrix 
suggested that maintenance of a suitable endonuclear 
PtdIns supply could be achieved via the action of a shut-
tling lipid transfer protein, such as PITP. Moreover, 
when coupled with the measured mass excess of endonu-
clear PtdCho to PtdIns in the nuclear matrix, a coupled 
endonuclear PtdIns-import/PtdCho-export cycle was also 
plausible. This shuttle hypothesis predicted that PITP 
localization to the nucleus is facilitated by PtdIns binding, 
and that PITP-deficient cells will be compromised for 
PtdIns import into the nucleus. We tested these two pre-
dictions in turn.
PtdIns-binding and PITP localization in the nucleus
A combination of genetic and structural data identifies 
a set of residues critical for coordination of the PtdIns 
Fig. 7. A: GPL composition of iMEF cells and puri-
fied envelope-free nuclei. Top row: GPL distribution 
by class for whole iMEFs and envelope-free iMEF nu-
clei (mean of n = 9 shown). The difference in compo-
sition between whole cells and nuclei for PtdOH 
(PA), PtdGro (PG), and PtdIns (PI) is highly signifi-
cant (P < 0.001), while the PtdCho (PC)/PtdEtn (PE) 
ratio is 1.85 for both whole cells and nuclei, with no 
significant difference. PtdSer (PS). B: Percent contri-
butions of saturated, monounsaturated, and polyun-
saturated species to PtdCho pool. The proportions of 
polyunsaturated and saturated PtdCho differ (P < 
0.01) between whole iMEFs and nuclei. C: The rela-
tive mass contribution of ether-linked PtdEtn species 
to the PtdEtn pool is substantially greater in whole 
iMEFs than in nuclei (P < 0.001).
class is a very minor constituent, at best, of the iMEF endo-
nuclear PL pool (data not shown).
PtdEtn, the second most abundant GPL in the nuclear 
matrix, accounted for some 28% of total endonuclear 
GPL mass. We observed interesting distinctions between 
nonnuclear and nuclear PtdEtn species. Ether-linked 
PtdEtn was substantially reduced in endonuclear fractions 
when evaluated as a percentage of the overall PtdEtn pool. 
In comparison to a fractional representation of 40.4 ± 
1.0% of bulk iMEF PtdEtn molecular species, only 27.7 ± 
1.5% of the mass of endonuclear PtdEtn species was ether-
linked (Fig. 7C, bottom row). The PtdCho/PtdEtn mass 
ratio, however, remained similar in endonuclear compart-
ments when compared with that ratio in bulk iMEF GPL, 
further confirming ether-linked PtdEtn species were genu-
inely segregated from the nuclear matrix.
Lipidomic profiling of the minor endonuclear PLs
While PtdCho and PtdEtn were the most highly repre-
sented GPLs in the endonuclear PL profile, envelope-free 
nuclei were relatively deprived of other GPL species (sup-
plementary Table 2). For example, PtdIns was depleted in 
the envelope-free nuclear fractions (1.5 ± 0.2% of nuclear 
GPL) as compared with whole iMEFs (5.6 ± 0.6% of bulk 
cellular GPL). The distribution by headgroup class (Fig. 7, 
top row) shows that the minor GPL classes (PtdOH, 
PtdIns, PtdGro) were all significantly reduced (in terms of 
fractional representation) in the most purified endonu-
clear fractions relative to PtdCho and PtdEtn. For pur-
poses of comparison, endonuclear PtdCho, PtdEtn, and 
PtdSer species accounted for 1.63, 1.77, and 1.13% of the 
corresponding total cellular pools. By contrast, PtdGro 
was particularly sparse, only 0.02% of the total iMEF pool 
was recovered in the nuclear matrix.
Endonuclear PtdOH and PtdIns comprised only 0.53 and 
0.42% of the corresponding total cellular pools. Interestingly, 
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experiments performed in HeLa cells, the localization 
profiles of all of the chimeras were also evaluated in 
pitp0/0 iMEFs and in Cos7 cells with similar results (data 
not shown).
The effects of the various missense substitutions on 
PITP localization profiles were not strictly dependent on 
the EGFP tag. HA-epitope-tagged versions of PITP, 
PitpT59D, PitpK61A, PitpN90L, and PitpE248K were also in-
dividually expressed in HeLa cells. The cells were fixed, 
permeabilized, and HA-PITP visualized by indirect im-
munofluorescence. The results largely recapitulated those 
obtained with EGFP-tagged chimeras (supplementary Fig. 
2). The nuclear signal was dominant in cells expressing 
PITP-HA, and this localization pattern was observed in 
97.6% of transfected cells (980/1,004). Predominantly cy-
tosolic distributions were observed for the PitpT59D-HA 
(78.3%; 548/700), and PitpE248K-HA expressing cells. For 
approximately 78% of cells expressing the PitpT59D-HA 
fusion protein, the fluorescence signal was predominantly 
cytoplasmic, and a nuclear localization defect was ob-
served in approximately 95.1% of cells transiently express-
ing the PitpE248K-HA  fusion  proteins  (448/471  cells; 
supplementary Fig. 2). Nuclear localization defects were 
less prominent in cells expressing PitpK61A-HA, with only 
15.6% of cells demonstrating a nuclear localization de-
fect. We do note that the nuclear signal in cells express-
ing PitpK61A-HA was most frequently of similar intensity 
to the cytoplasmic signal. It was rarely the dominant sig-
nal, as was observed for the PITP-HA control. Nuclear 
headgroup in the PITP binding pocket (37–39). Four 
mutant versions with specific defects in PtdIns-binding 
were employed in these experiments, PitpT59D, PitpK61A, 
PitpN90L, and PitpE248K. The corresponding missense 
substitutions were incorporated into the PITP-EGFP re-
porter for transient expression in HeLa cells and imaged. 
These constructs all produced stable proteins when ex-
pressed in cells, as confirmed by immunoblotting experi-
ments (data not shown). Individual cells were scored as to 
whether the chimera localized predominantly to the nu-
cleus or to the cytoplasm.
The PITP-EGFP reporter exhibited a predominant 
nuclear localization in 97.9% of the cells imaged (Fig. 8A, B). 
By contrast, PitpT59D-EGFP displayed a nuclear localiza-
tion defect in 51.6% of the cells imaged (190/368). Simi-
lar localization defects were scored for cells expressing 
PitpE248K-EGFP (61.4%, 189/308 cells). Milder, but nev-
ertheless significant, nuclear localization defects were also 
recorded for the PitpN90L-EGFP and PitpK61A-EGFP chi-
meras (17.7%, 57/322 and 10.8%, 40/370 of cells imaged, 
respectively). Those data suggested that PtdIns-binding 
influences either PITP import into or PITP export from 
the nucleus. The relationship was not simple, however. 
PitpS166A-EGFP and PitpS166E-EGFP chimeras [i.e., pro-
teins defective in both PtdIns and PtdCho-transfer activity 
(36, 39)] were fully competent for localization to the nu-
cleus. Some 2.7% (11/404) and 1.9% (8/425) of the cells 
imaged scored as showing defects in nuclear EGFP fluores-
cence, respectively. While the collective data reported 
Fig. 8. Nuclear localization patterns of PITP-EGFP 
and lipid binding mutants transiently overexpressed 
in HeLa cells. A: Confocal images of HeLa cells tran-
siently expressing PITP-EGFP and PITP PL bind-
ing and transfer mutants. Cells were grown on 
coverslips, transfected, and fixed 18 h posttransfec-
tion. Cells are counterstained with DAPI to examine 
nuclear localization of mutant constructs. WT PITP 
constructs produce nuclear fluorescence that is 
greater than or equivalent to cytoplasmic fluores-
cence in the vast majority of expressing cells. PtdIns-
binding defective point mutants, PitpT59D, PitpK61A, 
PitpN90L, PitpE248K, and the PtdIns/PtdCho-binding 
defective point mutants, PitpS166A and PitpS166E, 
were scored for the relative strength of nuclear signal 
versus cytoplasmic fluorescence, as judged by coinci-
dence with nuclear DAPI stain. B: Quantitation of 
nuclear localization defects in cells expressing PITP-
EGFP mutant constructs. Minimally 200 cells were 
scored for nuclear signal  cytoplasmic signal or if 
nuclear signal < cytoplasmic signal.
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of MEFs to efficiently incorporate these soluble head-
group precursors into GPL. However, we reproducibly 
detected reduced fractional incorporation of Ins-d6 into 
newly synthesized PtdIns in pitp0/0 MEFs. We do not pres-
ently understand either the underlying basis or the physi-
ological significance of this observation. By contrast, 
fractional rates of incorporation of newly synthesized 
PtdIns in endonuclear compartments was much slower in 
both PITP+/+ and pitp0/0 MEFs relative to fractional rates 
of incorporation of newly synthesized PtdCho (supple-
mentary Fig. 5C, D). Very little newly synthesized PtdIns 
was recovered from PITP+/+ or pitp0/0 endonuclear com-
partments during a 1 h pulse. Detectable incorporation 
required a pulse of at least 2 h. We interpret the data from 
these experiments to reflect the intrinsic ability of endo-
nuclear compartments to produce PtdCho in situ, while 
PtdIns is only slowly imported from extranuclear sources. 
Those rates of fractional incorporation of newly synthe-
sized PtdIns into pitp0/0 MEF endonuclear compartments 
were only modestly reduced (at best) relative to those 
measured for the PITP+/+ control (supplementary Fig. 
5C), and we do not consider these modest differences to 
be significant.
DISCUSSION
Herein, we describe a facile and reliable method suit-
able for purifying quality envelope-free nuclei from iMEFs 
and from primary MEFs. The choice of cell model was 
driven by the wealth of MEF lines that can be derived from 
mutant strains of mice. The method incorporated an ex-
panded repertoire of quality controls and defined criteria 
for purity. Particular attention was paid to the abundant 
integral membrane constituents of the membranes that 
constitute the greatest reservoirs for contamination (e.g., 
ER and nuclear envelope). This method reproducibly 
yielded purified nuclear particles that exhibited the dual 
properties of preserved ultrastructure and the essential ab-
sence of contaminating envelope. Quantitative phospho-
lipidomics of the iMEF endonuclear compartment leads 
us to three basic conclusions: First, in agreement with pre-
vious reports (9, 13, 14), the composition of the endonu-
clear GPL pool is distinct from that of bulk cell GPL. 
Second, the endonuclear GPL pool is not substantially 
enriched in saturated molecular species relative to the 
saturated/unsaturated  GPL-composition  of  the  bulk  
cellular pool. Third, the nucleoplasm is a GPL-poor envi-
ronment. Those latter two conclusions represent sig-
nificant departures from previous ideas regarding the 
fundamental properties of the mammalian endonuclear 
phospholipidome.
A GPL-deprived nucleoplasm
Mass measurements of the 42 detectable endonuclear 
GPL species demonstrated the nuclear matrix to be a PL-
poor environment. The endonuclear phospholipidome 
accounted for 1.4% of the total cellular GPL mass, and the 
GPL component occupied <0.1% of the volume of the 
localization defects were also scored in 25% of cells ex-
pressing PitpS166E-HA (34/137 cells imaged; supplemen-
tary Fig. 2).
Quantitative lipidomics of pitp0/0 iMEF nuclei
The capability to produce highly purified envelope-free 
MEF nuclei, when coupled with the availability of mutant 
MEF lines, made it possible to address previously intrac-
table questions regarding mechanisms of endonuclear 
lipid signaling. To that end, we first compared endonu-
clear GPL composition and content in PITP+/+ versus 
pitp0/0 iMEFs to test whether the mutant GPL profile was 
dramatically altered relative to that of the WT case. By the 
criteria of marker protein enrichment (supplementary 
Fig. 3A) and examination by EM (supplementary Fig. 3B, 
C), nuclei from pitp0/0 iMEFs were recovered to a compa-
rably high purity as from WT cells. Satisfyingly, composi-
tions of the whole cell and endonuclear phospholipidomes 
of both cell lines were also essentially indistinguishable 
(supplementary Fig. 4A, B). Moreover, the total PL con-
tent of the nuclear preparations was very similar for WT 
versus pitp0/0 iMEFs (1,039.5 ± 226.7 pmol/mg vs. 1,094.2 
± 217.5 pmol/mg nuclear protein, respectively).
Dynamic lipidomics analysis of PtdIns import into nuclei
The general requirement for PtdIns binding for effi-
cient localization of PITP to the nucleus was consistent 
with a nuclear PtdIns-supply activity for this protein, perhaps 
as a mechanism for sustaining a nuclear phosphoinositide 
signaling cycle. Although qualitative inspection of steady-
state nuclear PtdIns-4,5-P2 content by immunofluores-
cence staining did not suggest a major defect in nuclear 
pools of this phosphoinositide in PITP-deficient cells, a 
direct test of the PtdIns shuttle model required kinetic 
analysis of the nuclear PtdIns-import process in the pres-
ence and absence of PITP. To that end, standard pulse-
chase strategies were modified to estimate endonuclear 
dynamics of PtdIns and PtdCho lipidomics in PITP+/+ or 
pitp0/0 MEFs. Deuterated PL precursors (Cho-d9 and Ins-
d6) were used to label newly synthesized iMEF PtdCho and 
PtdIns in a pulse regimen, and precursor scan ESI-MS was 
used as readout to analyze the data. The ESI-MS analyses 
were conducted on whole cell lipid extracts as bulk con-
trol, and on lipids extracted from purified envelope-free 
nuclei as test case. Precursor scans of the Cho head-
group-derived m/z 184+ and m/z 193+ fragments over the 
mass range of 600–920 amu identified endogenous (i.e., 
preexisting) and newly synthesized PtdCho and SM spe-
cies, respectively. Precursor scans of the Ins headgroup-
derived m/z 241 and m/z 247 fragments over the mass 
range of 600–1,000 amu identified preexisting and newly 
synthesized PtdIns species, respectively. The light (pre- 
existing) species defined steady-state baselines for these 
measurements.
The fractional rates of Cho-d9 and Ins-d6 incorporation 
into whole cell lipid fractions were similar in PITP+/+ and 
pitp0/0 MEFs (supplementary Fig. 5A, B). Both newly syn-
thesized Cho- and Ins-GPL pools were readily measured at 
all time-points analyzed, and those data reflect the capacity 
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contamination from these systems dominated the GPL 
mass. As a result, the reported mass and compositional 
measurements were misinterpreted as reporting strictly 
endonuclear GPL pools. Such contamination issues lead 
to large overestimates of endonuclear GPL mass if the nu-
cleoplasm is a PL-poor environment. Indeed, as demon-
strated herein, simple detergent solubilization steps do 
not efficiently remove ER and nuclear envelope contami-
nants from nuclear fractions.
Implications for organization of nuclear GPLs
The reported abundance of endonuclear GPL, particu-
larly saturated PtdCho (14), in IMR-32 neuroblastoma cells 
posed the central question of how such a large PL load 
might be organized within the nuclear matrix. Standard 
solutions to the “PL-accommodation” problem, such as in-
corporation into membrane bilayers, are untenable. While 
invaginations of the nuclear envelope do extend into the 
nuclear interior, those structures are topologically distinct 
from the nuclear matrix itself (40, 41). Indeed, a hallmark 
feature of the nucleus is that it does not contain internal 
membrane-bound sub-compartments, despite the pres-
ence of morphologically and functionally distinct endonu-
clear domains (42). Alternatively, it is speculated that the 
large nuclear lipid-load provokes assembly of endonuclear 
PL into large aggregates or liquid crystalline phases (1, 3). 
In that regard, endonuclear PL “rafts” have been reported 
in hepatocytes (43–46), as have intranuclear lipid droplets, 
most strikingly under pathological conditions (47–49).
Nuclear lipid rafts and droplets are not common fea-
tures of other cell types, however, so hepatocytes seem un-
usual in this regard. Even so, the purported nuclear rafts 
are seen only in heavily processed hepatocyte nuclei (43–
46), and their identities as genuine rafts have not been 
directly confirmed by independent methods. If protein 
binding is a primary mechanism for nuclear lipid-organi-
zation, then the reported high nuclear abundance of GPL 
demands that a large fraction of nuclear protein be GPL-
associated. All of these general ideas lead to speculations 
that PtdCho and other GPLs may play significant struc-
tural roles within the nuclear matrix (14, 50). Such com-
plex issues surrounding mechanisms of PL-accommodation 
largely evaporate if the nuclear matrix proves to be a PL-
poor compartment, as our data indicate it to be. With the 
stoichiometries we measure, GPL-binding to resident pro-
teins alone could satisfy the PL-accommodation problem 
without the need for occupying a major fraction of nuclear 
protein with bound GPL. A GPL-deprived nuclear matrix 
also circumvents issues associated with a global gel-like 
physical environment formed by an abundance of satu-
rated GPL. Our conclusions are consistent with the results 
of multiple studies that describe the nucleoplasm as a 
highly dynamic environment where naive molecules, such 
as GFP, exhibit comparable diffusion coefficients in the 
cytoplasm versus the nuclear matrix [e.g., (34, 51)]. While 
involvements of GPLs in structural or organizational ca-
pacities within the nuclear matrix remain tenable, our 
data indicate any such involvements are most likely highly 
constrained and of a small scale.
iMEF nucleoplasm. Strict interpretations of those values 
are subject to several unavoidable caveats. First, removal of 
the nuclear envelope demanded manipulation of the or-
ganelle in progressively dilute detergent environments 
ranging from 1% NP-40 for the initial extraction, to 0.5 
and 0.33% NP-40 in the intermediate stages, and no deter-
gent in the final step. It is not clear how much of the base-
line endonuclear GPL pool was lost during those obligate 
NP-40-containing steps. We view this as an unknowable 
factor because it is not possible to assess the ground state 
of endonuclear GPLs prior to purification of envelope-
free nuclei for the comparison. But, the excellent repro-
ducibility of the data through independent preparations 
suggests the perturbations imposed are consistent and 
manageable.
Second, high resolution EM analyses consistently de-
tected trace amounts of membrane-like material in the 
most purified nuclear particle fractions. If those repre-
sented membrane remnants, such contaminants would 
have contributed to the GPL mass measured in the puri-
fied endonuclear fractions. The under-representation of 
PtdIns in the endonuclear GPL profiles relative to bulk 
cell membranes argues against contamination by bulk ER 
representing a major source of membrane contamination 
in these preparations, as ER is a PtdIns-rich membrane sys-
tem. Rather, the inner nuclear envelope would be a more 
likely source of membrane contamination, and our analy-
ses could not determine the extent to which the matrix 
leaflet of the inner nuclear envelope was removed. Be-
cause the lipids of this leaflet contact lamins and other 
abundant proteins of the nuclear periphery, this lipid pool 
is likely to be more resistant to stripping. What morpho-
logical state such remnants would assume during the prep-
aration of envelope-free nuclei is unknown. These might 
represent the membrane remnants discussed above, or we 
might have failed to recognize such contamination alto-
gether. Thus, the endonuclear GPL values reported 
herein, although low, may yet overestimate endonuclear 
GPL mass. However, we are encouraged with the repro-
ducibility of the quantitative measurements.
The values we measured for endonuclear GPL load di-
verge from those reported for the IMR-32 neuroblastoma 
cell line. That is, the only other cell line of which we are 
aware for which a quantitative analysis of the nuclear ma-
trix phospholipidome is described. A load of approxi-
mately 4 nmol PtdCho/106 nuclei was reported for those 
cells, along with the remarkable estimate that PtdCho 
alone occupies 12–16% of the IMR-32 nuclear volume 
(14). Why this large discrepancy between the two analyses? 
As both studies used 0.5–1.0% concentrations of nonionic 
detergent for solubilization of nuclear envelope, one for-
mal possibility is that different cell lines genuinely exhibit 
manifestly different endonuclear GPL loads. While cell 
line-specific variations will almost certainly prove to be the 
case, we consider it unlikely that such variations fully ac-
count for the approximately two order of magnitude range 
that  separates  the  two measurements. Rather, as ER/nu-
clear envelope remnants were not systematically moni-
tored in the previous study (14), we suspect membrane 
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signaling lipids by channeling these into production of 
more inert molecular species. Our identification of 38:4 
PtdIns as, by far, the most abundant endonuclear PtdIns 
molecular species, when only 36:2 PtdOH is detected in 
this same compartment in an essentially 1:1 stoichiometry, 
is interesting from this perspective. A simple nucleoplas-
mic phospholipase C-diacylglycerol kinase pathway will 
yield endonuclear 38:4 PtdOH. Perhaps this PtdOH is 
generated, but is rapidly and quantitatively remodeled to 
36:2 PtdOH in the nucleoplasm. Such a remodeling could 
occur via an endonuclear Lands cycle employing the sequen-
tial actions of phospholipase A2 and lyso-PtdOH acyltrans-
ferase (57). Alternatively, 38:4 PtdOH may be channeled 
into 38:4 PtdCho or 38:4 PtdEtn synthesis by nuclear isoforms 
of enzymes of the CDP-choline and CDP-ethanolamine 
pathways (14, 18). In either case, the physical context for 
how such enzymes register their substrates in the GPL-
depleted nucleoplasm remains an open and fundamental 
question. How (or even whether) the corresponding bio-
synthetic products are exported from the nucleoplasm 
also remains to be established.
Endonuclear lipid dynamics and metabolism
The open questions regarding the scale and nature of 
GPL signaling and metabolism in the nucleus, and how 
(or whether) GPLs shuttle into and out of the nucleo-
plasm, are difficult ones to experimentally address. As suit-
ably noninvasive methods with which to investigate these 
issues do not exist, the most tractable experimental ap-
proaches demand reliable methods to rapidly and effec-
tively purify envelope-stripped nuclear particles. These 
methods must yield endonuclear fractions with consistent 
properties, and the analytical platforms must be chaper-
oned by rigorously defined sets of quality controls. Herein, 
we describe one such method. Whether this particular pro-
tocol translates to other cell types, or whether it requires 
modification as a function of the specific application, re-
quires further investigation. The method does, however, 
provide a useful blueprint, and a set of quality control pa-
rameters, for development of nuclear matrix purification 
regimes suited for cell lines of interest to individual re-
searchers.
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